Summary
Semax is a synthetic heptapeptide developed from the 4–7 fragment of adrenocorticotropic hormone (ACTH), extended with a C-terminal proline-glycine-proline sequence that confers resistance to enzymatic degradation. It is studied in nootropic and neurotrophic literature.
Overview
Semax preserves the ACTH(4-7) sequence (Met-Glu-His-Phe), which is itself studied in neurotrophic-pathway literature, and adds a stabilizing C-terminal tripeptide. It is studied in research on BDNF expression, dopaminergic and serotonergic signaling, and cognitive-pathway model systems.
Research Background
Semax was developed at the Institute of Molecular Genetics in Moscow by Ashmarin and colleagues. Like selank, it draws on the Russian tradition of designing synthetic peptides based on bioactive fragments of larger endogenous sequences. Glazova, Manchenko, and others have published extensively on its preclinical pharmacology.
Mechanisms Studied
Mechanistic interest centers on BDNF expression, neurotransmitter-system modulation (dopaminergic and serotonergic), and the relationship between semax and the broader literature on ACTH(4-7) fragment biology. Cell-culture and animal-model literature has characterized its effects on these pathways.
Published Research Summary
Glazova et al. (2002) characterize neurotrophic effects of semax in animal models. Dolotov et al. (2006) report on BDNF expression following semax administration. Levitskaya et al. (2008) examine effects on monoaminergic systems.
Quality & Verification
For research compounds, lot-level documentation is the starting point for any analytical work. Researchers commonly examine batch-specific Certificates of Analysis, reversed-phase HPLC purity readouts, mass-spectrometry confirmation of molecular weight, and lot identification to evaluate compound identity, purity, and consistency before downstream experiments.